Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Retevmo

Drug and asset intelligence for Retevmo with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Mechanism of action

RET Inhibitor

Recent signals(3)

RegulatoryJuly 18, 2026

FDA Approves Supplemental Application for Retevmo (Selpercatinib)

The FDA has approved a supplemental application for Retevmo (selpercatinib) submitted by Eli Lilly.

ClinicalJune 16, 2026

Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer

Phase 3 LIBRETTO-432 results indicate an 83% reduction in the risk of disease recurrence or death with Retevmo as adjuvant therapy.

June 16, 2026

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

The Phase 3 LIBRETTO-432 study of Retevmo as adjuvant therapy in RET fusion-positive NSCLC will be highlighted at ASCO 2026.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Lilly — Retevmo

July 18, 2026 · N/A

Topline Data

Lilly — Retevmo

June 16, 2026 · N/A

Topline Data

Lilly — Retevmo

June 16, 2026 · N/A

Indications

RET fusion-positive lung cancer →

Therapeutic areas

Oncology · NSCLC →

Oncology · RET fusion-positive lung cancer →

Oncology · RET Inhibitor →

RET fusion-positive lung cancer →

RET Inhibitor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.